SEC Form 4 · accession 0001209191-19-003414
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pritesh Shah
Officer — Chief Commercial Officer
Period of report
Jan 9, 2019
Accepted (ET)
Jan 11, 2019 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 9, 2019 | M | 8,988 | $14.37 | A | 26,075 | D | |
| Ordinary SharesF1 | Jan 9, 2019 | S | 5,965 | $40.00 | D | 20,110 | D | |
| Ordinary SharesF1 | Jan 9, 2019 | S | 3,023 | $40.01 | D | 17,087 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF2 | $14.37 | Jan 9, 2019 | M | 8,988 | A | — | Feb 23, 2025 | Ordinary Shares | 8,988 | 8,751 | D |
Explanation of responses
- F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.
- F2Options exercised were fully vested as of the date hereof.